Barnes Group Inc. - B STOCK NEWS

BioArctic AB announced that its partner Eisai received Marketing Authorization from the MHRA in Great Britain for Leqembi (lecanemab) to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in specific adult patients. This marks the first authorization in Europe for a medicine targeting an underlying cause of Alzheimer's disease.

Lecanemab selectively binds to and clears toxic Aβ protofibrils from the brain. The approval was based on the Phase 3 Clarity AD clinical trial, which met its primary and key secondary endpoints. Common adverse reactions include infusion-related reactions and amyloid-related imaging abnormalities.

Eisai is working with health authorities to make Leqembi available to eligible patients. The antibody was originally developed by BioArctic, resulting from a collaboration with Eisai.

BioArctic AB (NASDAQ Stockholm: BIOA B) has addressed recent rumors circulating in British media regarding the imminent approval of lecanemab in Great Britain. The company stated that it has not been informed of any decision made by the relevant authorities and is therefore unable to comment on these speculations. BioArctic has committed to updating the market if new information becomes available. This statement was released for public disclosure on August 22, 2024, at 08:34 a.m. CET. The company has provided contact information for its VP of Communications and IR, Oskar Bosson, for further inquiries.

Barnes Group Inc. (NYSE: B), a global provider of engineered products and industrial technologies, has announced its participation in the 2024 Jefferies Industrials Conference. Thomas J. Hook, President and CEO, will present to investors on September 5, 2024, at 11:35 a.m. ET.

A live webcast of the presentation will be available on the company's website at www.onebarnes.com in the Investor Relations section. Investors can also access a replay for 90 days following the presentation. Barnes has noted that the conference date and time may be subject to change, with any updates to be posted on their website.

BioArctic AB (NASDAQ Stockholm: BIOA B) has announced the upcoming release of its second quarter report for April - June 2024 on August 29, 2024, at 08:00 a.m. CET. Following the report's publication, the company will host an audiocast with teleconference at 09:30 CET on the same day. CEO Gunilla Osswald and CFO Anders Martin-Löf will present and discuss the quarterly results, followed by a Q&A session. Investors, analysts, and media are invited to participate via webcast or teleconference. The webcast will be available on-demand on BioArctic's corporate website after the presentation.

ETQ, a Hexagon company, has appointed Prashant Darisi as Chief Product Officer. Darisi will manage the product roadmap for ETQ's quality management system (QMS) software platform, ETQ Reliance®. His responsibilities include expanding the software into new areas leveraging AI and predictive quality analytics, as well as integrating QMS with connected worker capabilities.

Darisi brings over 20 years of experience in executive positions, having previously served as Vice President and General Manager at Everbridge. He has expertise in enterprise SaaS products, AI/ML strategy, and product management. ETQ CEO Vick Vaishnavi expressed confidence in Darisi's ability to drive product strategy that will benefit customers globally, especially as ETQ explores integration opportunities within the Hexagon environment.

BioArctic AB's partner Eisai announced the approval of Leqembi (lecanemab) for the treatment of Alzheimer's disease in the United Arab Emirates (UAE). The approval is based on the successful Phase 3 Clarity AD study, where Leqembi met its primary and key secondary endpoints. Leqembi is the first approved treatment shown to reduce disease progression and slow cognitive decline by targeting amyloid-beta aggregates in the brain.

In the UAE, 4.09% of those over 60 have dementia, with Alzheimer's being the most common cause. Leqembi is already approved in several countries, including the U.S., Japan, and China. The antibody was originally developed by BioArctic, based on research by Professor Lars Lannfelt. Eisai is responsible for clinical development and commercialization, with Biogen commercializing in the UAE.

Helzberg Diamonds, a renowned US jewelry retailer, has partnered with Proximity, creator of the award-winning Retail Super-App, to enhance customer experience. The collaboration aims to empower sales associates with a clienteling platform that delivers hyper-personalized service across all touchpoints. Launched in summer 2024, the platform connects customer data and uses innovative technology to power personalization and provide endless aisle capabilities.

The partnership is expected to transform customer engagement, drive repeat purchases, and increase in-store efficiency. Proximity's CEO, Cathy McCabe, expressed excitement about forging deep connections with customers and cultivating loyalty. Brad Hampton, CEO of Helzberg Diamonds, highlighted the opportunity to accelerate their digital transformation while maintaining the human touch that sets them apart in the industry.

ETQ, a Hexagon company, has unveiled the latest version of its ETQ Reliance® NXG quality management system (QMS) software, featuring a new Inspection Management app. This innovative solution automates and streamlines the quality inspection process for discrete and process manufacturers. The app enables:

- Automation of processes
- Reduction of paperwork
- Real-time visibility into quality operations

Key benefits include always-current prescriptive inspection guidance, automatic linking to quality events, a flexible inspection plan framework, and comprehensive data reporting and analytics. The Inspection Management app aims to mitigate the cost of poor quality, ensure compliance at scale, and maintain customer trust.

Crawford & Company (NYSE: CRD-A, CRD-B) reported its Q2 2024 results, with revenues before reimbursements at $314.2 million, down from $324.6 million in Q2 2023. Net income attributable to shareholders increased to $8.6 million from $8.4 million last year, with diluted EPS at $0.17 for both share classes, unchanged from Q2 2023. Non-GAAP diluted EPS rose to $0.25 from $0.24. The company added $23 million in new business, with a robust pipeline.

Segment Results:

• North America Loss Adjusting: Revenues of $76 million, slight decline; operating earnings up to $4.9 million.
• International Operations: Revenues up 7.3% to $102.3 million; operating earnings rose to $5.7 million.
• Broadspire: Record revenues of $97.1 million, up 11.3%; operating earnings surged to $15.1 million.
• Platform Solutions: Revenues fell 40.8% to $38.8 million; operating earnings down to $1.5 million.

Company's debt rose to $233.8 million, with cash and equivalents at $46.7 million. Cash used in operations was $8.3 million for H1 2024, versus $27.2 million provided in 2023. No CRD-A shares were repurchased, but 230,861 shares of CRD-B were repurchased for $2.1 million.